The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 29, 2020
Filed:
Oct. 29, 2018
Applicant:
Nutritional Therapeutics, Inc., Islandia, NY (US);
Inventor:
Robert A. Settineri, Irvine, CA (US);
Assignee:
NUTRITIONAL THERAPEUTICS, INC., Islandia, NY (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/702 (2006.01); A61K 31/661 (2006.01); A61K 9/00 (2006.01); A23D 9/013 (2006.01); A61K 38/28 (2006.01); A61K 38/44 (2006.01); A61K 45/06 (2006.01); A61K 47/12 (2006.01); A61K 47/24 (2006.01); A61K 47/26 (2006.01); A61K 31/05 (2006.01); A61K 31/122 (2006.01); A61K 31/16 (2006.01); A61K 31/375 (2006.01); A61K 31/385 (2006.01); A61K 31/522 (2006.01); A61K 31/593 (2006.01); A61K 31/66 (2006.01); A61K 31/683 (2006.01); A61K 31/685 (2006.01); A61K 31/7028 (2006.01); A61K 31/716 (2006.01); A61K 31/733 (2006.01); A61K 33/22 (2006.01); A23L 29/10 (2016.01); A23L 29/244 (2016.01); A23L 33/105 (2016.01); A23L 33/115 (2016.01); A23L 33/12 (2016.01); A61P 39/06 (2006.01); A61P 21/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/702 (2013.01); A23D 9/013 (2013.01); A23L 29/10 (2016.08); A23L 29/244 (2016.08); A23L 33/105 (2016.08); A23L 33/115 (2016.08); A23L 33/12 (2016.08); A61K 9/006 (2013.01); A61K 9/0056 (2013.01); A61K 31/05 (2013.01); A61K 31/122 (2013.01); A61K 31/16 (2013.01); A61K 31/375 (2013.01); A61K 31/385 (2013.01); A61K 31/522 (2013.01); A61K 31/593 (2013.01); A61K 31/66 (2013.01); A61K 31/661 (2013.01); A61K 31/683 (2013.01); A61K 31/685 (2013.01); A61K 31/7028 (2013.01); A61K 31/716 (2013.01); A61K 31/733 (2013.01); A61K 33/22 (2013.01); A61K 38/28 (2013.01); A61K 38/44 (2013.01); A61K 38/446 (2013.01); A61K 45/06 (2013.01); A61K 47/12 (2013.01); A61K 47/24 (2013.01); A61K 47/26 (2013.01); A61P 21/00 (2018.01); A61P 39/06 (2018.01); C12Y 111/01006 (2013.01); C12Y 115/01001 (2013.01); A23V 2002/00 (2013.01);
Abstract
A method of oral delivery of phospholipid/inulin compositions comprising capsules, tablets, chewable wafers or powdered material in a liquid carrier in quantities effective for treating systemic pain from fibromyalgia. The compositions further including effective amounts of caffeine also reduces fatigue and enhances alertness and focus.